

FOSUN

A GLOBAL
INNOVATION-DRIVEN
CONSUMER GROUP



FOSUN, TOWARDS A BRIGHTER LIFE

Fosun was founded in 1992. After more than 30 years of development, Fosun has become a global innovation-driven consumer group. Adhering to the mission of creating happier lives for families worldwide, Fosun is committed to creating a global happiness ecosystem fulfilling the needs of families worldwide in Health, Happiness and Wealth. In 2007, Fosun International Limited was listed on the main board of the Hong Kong Stock Exchange (stock code: 00656.HK).

MISSION

Creating happier lives for families worldwide

VISION

Rooted in China, Fosun is committed to creating a global happiness ecosystem fulfilling the needs of families worldwide in Health, Happiness, and Wealth

VALUES

Self-improvement, Teamwork, Performance, and Contribution to Society

87.28 billion

Total revenue in 1H2025

735.7 billion

Total assets as at 30 June 2025

3.15 billion

Industrial operation profit¹ in 1H2025

53%

Proportion of overseas revenue in 1H2025

3.6 billion

Investment in technology and innovation² in 1H2025, with more than 20 global technology innovation centers established

AA

MSCI ESG rating

* Currency is in RMB and financial data is based on the interim results for the six months ended 30 June 2025, unless otherwise specified


¹ It includes the profit contribution of industrial operation subsidiaries of the Group and associates and joint ventures accounted by equity method of the Group

² It includes scientific research investment (expensed and capitalized) but excludes digitalization expenses

ROOTED IN CHINA, DEVELOPING GLOBALLY

FOSUN

Rooted in China, Fosun has been developing globally and has long adhered to the two core growth drivers of “innovation” and “globalization”. Fosun is one of the few Chinese companies that is equipped with global operation and investment capabilities, and has accumulated profound technology and innovation capabilities.



OUR STRATEGIES

Fosun adheres to its globalization strategy, continuously innovates to create new momentum, and remains focused on deepening its development in the household consumption industry



Globalization

Innovation


MARKET

SET

01

PROFOUND GLOBAL OPERATIONS

The globalization journey of Fosun began with the listing of Fosun International in Hong Kong. After 18 years since its listing, Fosun has established a business presence in more than 40 countries and regions around the world. Since 2022, the model of “global organization + local operations” has become more mature. Operations are at the core of Fosun’s future globalization.



PROFOUND GLOBAL OPERATIONS

Fosun's globalization strategy emphasizes "combining global resources with China's capabilities". It not only promotes the "two-way engagement" between the global and Chinese markets, but also encourages the endogenous development of its ecosystem enterprises both domestically and internationally, actively expanding their businesses beyond their home markets.

Promote Overseas Expansion of Products and Services



DPP-1 Inhibitor

The small molecule orally administered DPP-1 inhibitor independently developed by Fosun Pharma achieved overseas licensing for a potential total of US\$645 million.

FXS6837

FXS6837, a small molecule inhibitor with independent intellectual property rights owned by Fosun Pharma, for the treatment of diseases in the field of immunomodulation achieved overseas licensing.

HANQUYOU

Since its launch five years ago, the independently developed HANQUYOU has been approved for marketing in over 50 countries and regions, with more than 7.5 million units shipped globally and out-licensing agreements covering over 100 countries and regions, benefiting over 260,000 patients worldwide.

HANSIZHUANG

The independently developed HANSIZHUANG is the world's first and the only anti-PD-1 monoclonal antibody approved in the European Union for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). It subsequently received approvals in the United Kingdom and India, and has been launched in over 30 countries and regions.

HLX14 & HLX11

Biosimilar drugs, HLX14 and HLX11, officially received Good Manufacturing Practice (GMP) certificate issued by the Federal Agency for Medicines and Health Products (FAMHP) of Belgium; HLX14 has been approved for marketing in the United States.

Yuyuan Lantern Festival

Themed on "Adventure of Mountains and Seas", Yuyuan Lantern Festival made another international appearance to celebrate the 50th anniversary of the establishment of diplomatic relations between China and Thailand. Held for 50 days along the Chao Phraya River in Thailand, the event attracted over 4 million visitors.

46.67 billion

Overseas revenue in 1H2025

53%

Overseas revenue proportion in 1H2025

Establish a Global Presence of Quality Assets



Fidelidade

Fidelidade has maintained its leading position in Portugal and received its initial coverage from S&P with an "A" rating. In the first half of 2025, its international operations accounted for 28.2% of total consolidated business and overseas gross written premiums reached EUR924 million.

Fosun Pharma

Fosun Pharma reached a strategic cooperation with Saudi Arabia's comprehensive healthcare group, Fakeeh Care Group, to jointly promote the local introduction of innovative therapeutic products in Saudi Arabia.

Club Med

Club Med's business volume once again reached a record high of RMB9.25 billion in the first half of 2025, representing a year-on-year increase of 3.8%

Hainan Mining

Hainan Mining commenced pilot production at Phase 1 of the Bougouni lithium mine in Mali. Leveraging its established projects such as the Bougouni lithium mine in Mali, Roc Oil oilfield project in Malaysia and the recently acquired oilfield project in Oman, Hainan Mining is accelerating the building of a "Minerals + Energy" network spanning West Africa, the Middle East, and Southeast Asia. Revenue from overseas operations has now increased to 57% of total revenue.

Easun Technology

Easun Technology formed a joint venture with Saudi enterprise, Khaled Juffali Company, to provide production line solutions for Saudi Arabia's electric vehicle industry and has already received its first order.

TECHNOLOGY-LED & INNOVATION-DRIVEN

FOSUN

Global R&D has created multiple “China’s first” and the “World’s first” innovations.

3.6 billion

Investment in technology
and innovation¹ in 1H2025

20+

Global technology
innovation centers

R&D Innovation

Fosun Pharma

A total of 5 indications of 4 innovative drugs independently developed and licensed-in by Fosun Pharma have been approved for launch both domestically and internationally, 4 innovative drugs have entered the pre-launch approval stage.

FUMAINING (lucumetinib tablets)

Fosun Pharma’s FUMAINING (lucumetinib tablets) has been approved for two indications and officially launched for clinical use, filling the treatment gap in the field of rare tumors.

HLX43

Henlius’ HLX43, a PD-L1-targeting antibody-drug conjugate (ADC) currently in global Phase II clinical trials, has demonstrated notable competitiveness in terms of drug safety, efficacy, and R&D progress, and holds strong potential to become a broad-spectrum anti-cancer drug.

HLX22

HLX22, an innovative anti-HER2 monoclonal antibody, became the world’s first anti-HER2-targeted therapy for gastric cancer to receive Orphan Drug Designation (ODD) from both the European Union and the United States.

Yi Kai Da (ejilunsai injection)

China’s first approved CAR-T cell therapy, Yi Kai Da (ejilunsai injection), has benefited over 800 lymphoma patients.

Domestically produced Da Vinci Xi Surgical System

The Da Vinci surgical system has been successfully localized and commercialized domestically.

Ion Robotic Bronchoscopy

The Ion Robotic Bronchoscopy (the Ion System) has been successfully approved for launch and commercialization in Chinese mainland, serving over 200 patients to date.

Technology Innovation Centers in Various Fields

- Fosun Pharma Global R&D Center (national level)
- Fosun Pharma North America R&D Headquarters
- Fosun Pharma Academician Expert Workstation
- Jiangsu Wanbang Recombinant Protein Drug Engineering Center
- Jiangsu Wanbang Engineering Research Center for Diabetic Drugs
- Chongqing Yao Pharma National-Local Joint Research Center for Lyophilized Preparations
- Chongqing Pharmaceutical Research Institute
- Liaoning AVANC Pharma Professional Technology Innovation Center for Tumor and Perioperative Drugs
- Foshan Fosun Chancheng Hospital Tumor Precision Key Laboratory
- Henlius Global Innovation Center
- Fosun Kairos R&D Center
- Intuitive Fosun Headquarters Industrial Base
- Wansheng Technology Center (national level)
- Easun Technology Global R&D Center
- Sichuan Engineering Technology Center for Intelligent Brewing of Baijiu
- Tianjin Seagull High-Precision Mechanical Watch Enterprise Key Laboratory
- Fosun Cosmetics Global Innovation Center (CNAS certified)
- Yuyuan Foods & Dining Group Innovation Center
- Fosun Wine & Spirits Global Innovation Center
- Yuyuan Jewelry Creative House
- Lanvin Group Fabric Innovation Center

¹ It includes scientific research investment (expensed and capitalized) but excludes digitalization expenses

ALL IN AI: AI APPLICATIONS EMPOWERING TOMORROW

Fosun's AI strategy aims to lead the industry in AI adoption, evolving from "business + AI" to "AI + business".

AI Applications



CONSULTING
SERVICES

PharmAID decision intelligence platform

Fosun Pharma has launched the industry's first decision intelligence platform, harnessing AI to empower drug R&D. By integrating multiple global clinical information and pipeline databases, it supports strategic planning of high-value pipelines and enhances R&D quality and efficiency.

HenliSciAI platform

Henlius' HenliSciAI platform supports the identification of new drug targets, significantly boosting drug discovery efficiency.

AI G.O

FTG has entered into a full-stack AI collaboration with Alibaba Cloud to develop the cultural tourism intelligent system, "AI G.O". This system is designed to optimize the entire vacation experience and enhance operational efficiency, with an official launch scheduled for late September 2025.

G.M Copilot

Club Med's G.M Copilot, an industry-leading conversational AI assistant for consumers, serves over 12 markets worldwide and handles 12,000 conversations monthly with a 30% automation rate.

GAMA

Fidelidade has introduced AI-powered process solutions for intelligent document processing, customer inquiries, and claims processing, accelerating workflows and improving quality to achieve faster customer responses and higher satisfaction.

LEVERAGE THE FLYWHEEL STRATEGY TO DEVELOP HIGH-QUALITY PROJECTS WITH ASSET-LIGHT OPERATIONS

Building on its profound industrial operation capabilities accumulated over 30 years, along with its advantages in innovation and globalization, Fosun has joined hands with various partners to deploy advantageous industries and develop high-quality projects.



Fosun Pharma

Fosun Pharma together with the Shenzhen Guidance Fund and other investors established a RMB5.0 billion biopharmaceutical industry fund, managed by Fosun Health Capital.

Construction of Taicang Alps Resort Phase II officially underway

Funded by the Taicang Municipal Government with a total investment of approximately RMB5 billion and managed by FTG, construction of the Taicang Alps Resort Phase II project officially commenced.

Chongqing China Mall

FTG signed a cooperation agreement with the Chongqing Municipal Government platform to take on the renovation and operational management of the Chongqing China Mall Project under an asset-light model, creating a large-scale indoor themed tourism and entertainment park.

Asset-light operation in Jinsha Bay, Shenzhen

FTG signed an asset-light operation agreement for the Jinsha Bay project in Shenzhen, marking the launch of the first Club Med in the Greater Bay Area.

Club Med

85% of Club Med resorts have adopted a leasing and management model.

"Health care + Insurance"

The "health care + insurance" ecosystem policy model has deeply driven product innovation, generating RMB11.2 billion in premiums. Pramerica Fosun and Fosun United Health Insurance both reported year-on-year growth in first-year premiums and total premiums.

PROMOTE FC2M ECOSYSTEM SYNERGY & INNOVATE FES MANAGEMENT SYSTEM

F C2M

FOSUN/
FAMILY

Diversified
structure

CLIENTS

Membership
system


LINK

Flexible
Resilient

PRODUCTS &
SERVICES

Innovative R&D
High margins

FULL-CHAIN DIGITAL INTELLIGENTIZATION



PROFOUND INDUSTRY OPERATIONS + INDUSTRIAL INVESTMENT

MANAGEMENT
SYSTEM

FACING THE
FUTURE

VALUE
CREATION

TALENT, THE MOST VALUABLE ASSET OF FOSUN

FOSUN

A robust team of talent determines the scalability of the company's future development.

ELITE MANAGEMENT TEAM

160+ global partners
490+ industry partners
470+ functional line partners
50+ innovation partners

GLOCAL

30+ overseas global partners from
countries including Portugal, France,
Germany, the United Kingdom, Japan,
India, and the United States

TALENT DEVELOPMENT STRATEGY

Attract talent with development,
appraise talent based on performance,
train talent through work, and
unite talent with career opportunities



OUR
BUSINESSES

Fosun continues to focus on its four major business segments: Health, Happiness, Wealth, and Intelligent Manufacturing, providing high-quality products and services to families worldwide.

Its four core subsidiaries – Fosun Pharma, Yuyuan, Fosun Insurance Portugal (Fidelidade), and FTG – generated a total revenue of RMB63.61 billion in the first half of 2025, accounting for 73% of the Group's total revenue.

02

HEALTH

HAPPINESS

WEALTH

INTELLIGENT
MANUFACTURING

HEALTH SEGMENT

Continue to drive global industrial innovation to create a medical-grade, one-stop, all-scenario health ecosystem

FOSUN

BIOPHARMACEUTICALS

Through an open and globally integrated pharmaceutical R&D system with independent R&D, co-development, license-in and industrial investment, Fosun's Health segment focuses on core therapeutic areas including oncology (solid tumors and hematologic malignancies) and Immune-inflammatory disorders. Fosun places special emphasis on strengthening key technology platforms for antibodies and antibody drug conjugates (ADC), cell therapies and small molecules, while deploying frontier technologies such as radiopharmaceuticals, RNA therapeutics, gene therapies and AI-powered drug R&D through industry funds.

FOSUN PHARMA
复星医药

 **Henlius**

FOSUN KAIROS
复星凯瑞

FOSUN IDGENVAX
复星安特金

 **Gland**

DEVICES & DIAGNOSTICS

Medical aesthetics, respiratory health, professional medical devices, and medical diagnostics.

FOSUN MEDTECH
复星医疗器械

FOSUN DIAGNOSTICS
复星诊断

 **sisram**
medical

 **博毅雅**

FOSUN INSIGHTEC
复星医视特

INTUITIVE FOSUN
直观复星

HEALTHCARE SERVICES

Focusing on high-quality medical and professional services, the offerings include combined insurance, health consumption, and wellness solutions, designed to create a comprehensive closed-loop solution.

FOSUN HEALTH
复星健康

 **佛山复星禅诚医院**
FOSHAN FOSUN CHANCHENG HOSPITAL

 **JOYFUL WAY**
卓尔荟

LUZ SAÚDE

 **复星杏脉**
FOSUN AITROX

 **健嘉医疗**
JIANBA HEALTHCARE

FOSUN PHARMA

复星医药

FOSUN

A GLOBAL LEADING INTEGRATOR OF
PHARMACEUTICAL AND HEALTHCARE INNOVATION

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a global innovation-driven pharmaceutical and healthcare industry group with deep roots in China. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its presence in the pharmaceutical distribution and retail business.

19.4+ billion

Operating revenue in 1H2025

4.3 billion

Revenue from innovative drugs

2.584 billion

R&D investment in 1H2025, with innovative drug R&D investment increasing year-on-year

INNOVATIVE R&D PLATFORMS

Global R&D Center

Small molecule innovative drug platform
Collaboratively developed compounds
Radiopharmaceutical technology platform
Autoimmune disease field

Henlius

Antibody, ADC, and other large molecule technology platforms

Fosun Kairos

Cell therapy technology platform

Pharmaceuticals

Innovative drugs
Mature products and manufacturing
Vaccines

Medical Devices and Medical Diagnostics

Medical devices
Medical diagnostics

Healthcare Services

Online medical service platform
Offline medical institutions (including rehabilitation medical institutions)

HAPPINESS SEGMENT

Center on family consumption and cultural tourism to build a global, industry-wide happiness ecosystem

FOSUN

FAMILY CONSUMPTION

Leverage fashion and diverse experiences to drive family consumption.



LANVIN GROUP
复朗集团



DJULA
DJULA



AHAVA

WEI

LANVIN

sergio rossi



ST. JOHN



CULTURAL TOURISM BUSINESS

Provide families worldwide with "vacation-like lifestyle" and "lifestyle-based vacation". By aligning global resources, Fosun aims to create "super tourism destinations" to amplify the "tourism+" effect.

FOSUN Holiday
复星旅文

Club Med
地中海俱乐部

ATLANTIS
三亚·亚特兰蒂斯

太仓阿尔卑斯国际度假区
TAICANG ALPS RESORT

丽江地中海国际度假区
LIJIANG CLUB MED RESORT

豫园股份
YUYUAN Inc.



FOSUN

A WORLD-CLASS HAPPINESS CONSUMER GROUP

Yuyuan, with a portfolio of 19 China time-honored brands, 8 intangible cultural heritage projects at the municipal level or higher, and a range of leading brands, leads the trend of Chinese cultural revival through oriental lifestyle aesthetics. As the first batch of Chinese commercial stocks, Yuyuan leads the trend of Chinese cultural revival and develops a world-class happiness consumer group rooted in China.

19.1+ billion

Operating revenue in 1H2025

76%

Revenue proportion from
consumer industries

4,263

Jewelry and fashion stores

Nearly 19 million

Customer traffic in Yuyuan
Garden Malls in 1H2025



FOSUN Holiday

复星旅文

Fosun Tourism Group (also known as "FTG" and "Fosun Holiday"), is a world-leading leisure-focused integrated tourism group. Embracing the mission of "Better Holiday, Better Life", FTG endeavors to pioneer holiday lifestyle and create a world-leading family leisure and tourism ecosystem.

A WORLD-LEADING LEISURE-FOCUSED INTEGRATED TOURISM GROUP

10.23 billion

Business volume from tourism
operation in 1H2025

Nearly 70

Hotels and resorts

40+

Countries and regions with
sales and operations

24

Ski resorts

Club Med Global

Establish a global
presence by connecting
sun and snow resources
to build a premium resort
network

Club Med China

Cater to local consumer
demand, activating both
regional and urban
vacation scenarios

Super Resorts

Centered on major
attractions, integrate
diverse mixed-use
developments

Super Cultural Tourism Malls

Redefine urban commerce
through content and
performances, revitalizing
existing commercial spaces

WEALTH SEGMENT

Focus on the two major fields of insurance and asset management to build the Fosun Wealth ecosystem

FOSUN

INSURANCE

Establish a global presence and adhere to innovative development and insurance ecosystem development.

FIDELIDADE
SEGUROS DESDE 1808

 复星保德信
Pramerica FOSUN

PeakRe >

FOSUN HEALTH
福寿联合健康保险

La Positiva
Seguros

INVESTMENT MANAGEMENT

Leverage industrial investment + financial investment as twin drivers to empower Health, Happiness, Wealth, and Intelligent Manufacturing in every stage of life.

Millennium
bcp

FOSUN CAPITAL
复星创富

复星
锐正 **FOSUN**
RZ CAPITAL

FOSUN WEALTH
复星财富控股

HAFS

Rio Bravo

HIVE ASSET MANAGEMENT

Introduce industries to cities to facilitate urban development, creating a global urban hive benchmark.

FOSUN HIVE
复星蜂巢

FORTE 复地
汇世界 会生活

GRAND YUYUAN
大豫园


 **BFC** THE BUND
FINANCE CENTER
外滩金融中心

IDÉRA
CAPITAL MANAGEMENT

 **PAREF**

RESOLUTION
PROPERTY

 **28**
LIBERTY



Fidelidade is the market leader in Portugal, both in life and non-life segments. Guided by the values of "experience, innovation, overcoming and proximity", Fidelidade conducts its activity with a "Customer Centric Approach" strategy.

A LEADING GLOBAL INSURANCE COMPANY IN PORTUGAL

LOCAL LEADERSHIP

- Market share in Portugal stood at around 30%
- Maintained the top market share in Portugal

INTERNATIONAL DEVELOPMENT

- International operations accounted for 28.2% of total consolidated business
- Maintained a leading position in markets such as Peru and Bolivia

INNOVATIVE AI APPLICATIONS

- By adopting AI technologies, the rate of fully automated processing for motor claims rose from 48% as at the end of 2023 to 66% as at end-June 2025

A S&P rating

- International rating agency S&P initiated coverage
- Fitch rating maintained at "A+"

INTELLIGENT MANUFACTURING SEGMENT

With strategic resources, functional new materials, and intelligent manufacturing as the core, Fosun empowers high-end, intelligent and green transformation of the industry



海南矿业
HAINAN MINING

Green & Low-Carbon Resources

Leverage iron ore, oil and gas, and new energy to establish a foothold in strategic resources and energy

- Iron ore business steadily progressing: production from self-mined raw ore has reached full capacity for three consecutive years, with orders from strategic and long-term contract customers accounting for approximately 75% of total sales.
- Oil and gas business flourishing: oil and gas production capacity has significantly increased for three consecutive years; acquired oil interests in four oil blocks in the Sultanate of Oman.
- New energy business advancing smoothly: the lithium hydroxide (Phase I) project has produced qualified products, and the Bougouni lithium mine (Phase I) in Mali, Africa has achieved continuous production.



万盛股份
WANSHENG

Functional New Materials

Achieve breakthroughs in advanced materials core technology to support the upgrading of high-end manufacturing

- Global strategic expansion: established subsidiaries in Mexico, Singapore, and Thailand, and initiated the construction of a production base in Thailand.
- Accelerated technology innovation: RDP product purification technology contributed to the development of international standards, with 28 product/process-related projects launched.
- Product matrix expansion: acquired Guangzhou Shine Polymer to expand product categories and explore new business areas.



翌耀科技
ERAY TECHNOLOGY

Industrial Automation and Digitalization

A leader in intelligent manufacturing systems, facilitating the intelligent transformation of the manufacturing industry

- Technology sharing drives new global market breakthroughs: successfully launched a complete final assembly workshop project in Saudi Arabia, expanding new business into Argentina.
- Leveraging strategic equity investments to build ecosystem advantages: establishing a differentiated product portfolio and enhancing industrial investment by acquiring equity interests in specialized companies.
- Deep integration of AI and digital technologies: creating an intelligent service ecosystem to achieve end-to-end intelligent upgrades from design to manufacturing.

REMARKABLE ESG ACHIEVEMENTS

For a brighter life

AA MSCI ESG

Rating maintained at AA for four consecutive years

AA- HSI ESG

Top 5%

S&P ranking among global peers

3.9

FTSE Russell ESG score

Included in S&P Global's "Sustainability Yearbook 2025" and ranked among the top 1% in S&P Global's "Sustainability Yearbook 2025 (China Edition)"

Continuously recognized as a constituent of the FTSE4Good Index

CARBON NEUTRALITY STRATEGY

- Strive to peak carbon emissions by 2028 and achieve carbon neutrality by 2050
- EHS management framework
- Climate risk response

FOSUN FOR GOOD

- Rural Doctors Program
- Assist WHO in building a malaria-free world

CORPORATE GOVERNANCE

- Continue to optimize and evolve corporate risk management
- Improve ESG governance structure
- Proactive two-way communication
- Strengthen information disclosure based on GRI standards and Hong Kong Stock Exchange's New Climate Requirements

E

S

G

03

FOSUN FOR GOOD

Established in 2012, Fosun Foundation serves as the principal philanthropic entity of Fosun and is recognized as a “5A Social Organization” in China. Upholding Fosun’s corporate value of “Contribution to Society”, the foundation carries out public welfare activities in the fields of global emergency relief, rural revitalization, healthcare support, youth entrepreneurship, education, and culture & art, etc., with its initiatives reaching numerous countries and regions worldwide.

Regarding rural revitalization, the Rural Doctors Program trains and retains qualified rural doctors, and enhances the capacity and accessibility of primary healthcare services to reduce poverty and the risk of returning to poverty caused by illness, supporting the “Healthy China 2030” vision. Regarding youth entrepreneurship and education, the Protecting Open Innovation Program empowers global youth in the AI+ era to realize their entrepreneurial dreams. The Emerging Visionaries Award encourages young people to advance the United Nations Sustainable Development Goals (SDGs) through innovative public welfare projects, empowering Chinese youth to bring their philanthropic efforts onto the global stage. In response to sudden global disasters, Fosun Foundation embodies the humanitarian spirit by swiftly providing relief support and care to affected areas.





RURAL DOCTORS PROGRAM

Rural doctors are the "gatekeepers" of grassroots health. In late 2017, under the guidance of the National Health Commission Poverty Relief Office, Fosun Foundation, together with China Population Welfare Foundation and other units, initiated the Health by Heart - Rural Doctors Program ("Rural Doctors Program"), which focuses on safeguarding, empowering and incentivizing rural doctors, implementing a comprehensive support plan centered around the 5 "One Action" to protect grassroots health.

422

On-site workers

78

Counties covered in 16 provinces, cities and autonomous regions

25,000

Rural doctors served

3

million

Rural families benefited

16.34

million

Rural residents benefited



FIGHT AGAINST MALARIA WORLDWIDE

Second-generation artesunate for injection, Argesun®

Argesun®, the second-generation artesunate for injection has become the first artesunate injectable presented with a single solvent system that received World Health Organization prequalification (WHO PQ), greatly enhancing convenience for clinical use.

33

Antimalarial drugs prequalified by WHO

420

million

As at 30 June 2025, Fosun Pharma had supplied a cumulative total of over 420 million doses of artesunate for injection globally

84+

million

Artesunate for injection has saved the lives of more than 84 million patients with severe malaria



FOSUN FOUNDATION 复星艺术中心



The first 3A social organization among Shanghai contemporary art institutions



The first governing unit of Shanghai Art Museum Association



Shanghai Municipal Administration of Culture and Tourism's "Civilization and Integrity, Art Appreciation" co-construction unit, Shanghai Public Welfare Base, Donghua University Aesthetic Education Practice Base



40+ art exhibitions

Committed to presenting international and Chinese contemporary art exhibitions and special exhibitions with rich content, including "Tadao Ando: Endeavors", "Yayoi Kusama: All About Love Speaks Forever", "Liu Jianhua: Metaphysical Objects", etc.

2 million+ visitors

600+ public education campaigns

Insist on organizing high-quality public education campaigns to help the public understand art and promote active participation in art-related events

50,000+ participants in public education campaigns

500+ Fosun Foundation (Shanghai) Night and Aesthetic Journey

Organize diversified and comprehensive cross-brand activities to promote public awareness and public engagement in the latest contemporary art trends

Fosun Foundation (Shanghai) aims to promote contemporary art and is committed to binding Chinese and international art and culture, and promote public awareness, understanding and engagement in global contemporary art. Fosun Foundation (Shanghai) continues to support local Chinese artists, providing a broad display platform for outstanding Chinese contemporary art works. Fosun Foundation (Shanghai) is located in the Bund Finance Center. Fosun Foundation (Chengdu) was opened in June 2022. Fosun Foundation (Shanghai) participates in, witnesses and leads the development of contemporary art and culture. As an art consultant, Fosun Foundation (Shanghai) has long showcased its collection of Chinese art works in global landmark buildings such as 28 Liberty in New York to promote global cultural and artistic exchanges

FOSUN

TOWARDS A BRIGHTER LIFE



WeChat



Weibo



WeChat Channels



Douyin

HONG KONG

Room 808, ICBC Tower, 3 Garden Road,
Central, Hong Kong
Tel : +852 2509 3228
Fax : +852 2509 9028

SHANGHAI

The Bund Finance Center, No. 600 Zhongshan
East 2nd Road, Huangpu District, Shanghai
Tel : +86 21 2315 6666
Fax : +86 21 6130 3288
Postal Code : 200010